MOR208 (formerly XmAb5574) is a potent anti-CD19 antibody with a proprietary modification to the Fc portion, that is being developed to treat B-cell malignancies.
The open-label, multi-dose, single-arm, dose-escalation study was designed to assess the drug’s safety, tolerability, pharmacokinetic profile and preliminary anti-tumor activity.
The company expects to report the data from the trial in the fourth quarter 2012.
MorphoSys chief development officer Arndt Schottelius said, "The extended treatment period we were able to include in the phase 1 study could provide us with additional data on preliminary anti-tumor activity."
MorphoSys and Xencor signed a worldwide exclusive license and collaboration agreement for MOR208 in June 2010.
According to the agreement, MorphoSys will be exclusively responsible for further clinical development after successful completion of the Phase I trial.